Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

Once again a post ignores the facts of subgroup analysis and mischaracterizes it as misdirection. Performing subgroup reporting identifies which patients the next study should focus and for which patients the treatment might not benefit. This is what the FDA wants to see in both an accelerated pathway approval as well as the next clinical protocol. I’m great full that Leo shred this with us, and yes he probably needed to release the subgroup data to point out that for some patients Brilacidin rinse appeared to be most responsive, beyond the 20% improvement over the placebo of the general study population.